Objective: To evaluate the cost-effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of community-acquired complicated intraabdominal infections accounting for development of antibiotic resistance in the Dutch setting. Methods: A decision tree was developed to estimate cost-effectiveness of ertapenem versus piperacillin/tazobactam at different time points after introduction of treatment. Development of resistance was incorporated using a compartment model. Resistance was a function of the eradication rate of pathogens and antibiotic prescription. Model outcomes included quality-adjusted life years (QALYs), direct costs and cost per QALY saved. Microbiological eradication rate, clinical success, and costs were derived from literature. The analyses included pathogens with intrinsic or acquired resistance. Results: The model suggested overall savings of €355 (95% uncertainty interval €480; €1205) per patient when abdominal infections are treated with ertapenem instead of piperacillin/tazobactam. Probabilistic sensitivity analysis found a 94% probability of the incremental cost per QALY saved being within the generally accepted threshold for cost-effectiveness (€20,000). After 5 years, it is expected that antibiotic resistance with piperacillin/tazobactam has increased with a greater rate compared to ertapenem, and cost-savings with ertapenem are expected to increase to €672 (€-232; €1617). Ertapenem will, in addition, result in greater success rates and in QALY savings (0.17; 0.07-0.30). Alternative scenarios, with lower levels of initial resistance confirm the cost savings with ertapenem. Conclusion: Given the underlying assumptions and data used, this evaluation demonstrated that ertapenem is a cost saving and possibly an economically dominant therapy over piperacillin/tazobactam for the treatment of community-acquired intraabdominal infections in The Netherlands.
Introduction
Complicated intraabdominal infections (IAI) are commonly observed in surgical practice and can contribute to unfavorable outcomes (e.g., morbidity and mortality) [1] . IAIs are defined as the presence of a purulent exudate in the abdominal cavity caused by, for example, abdominal surgery, trauma, or organ perforations [2] . Complicated IAI extend beyond the hollow viscus of origin into the peritoneal space and are associated with abscess forming or with peritonitis [3] . It is estimated that approximately 80% of all IAI are community acquired; i.e., infections contracted outside of a hospital setting [1] . The infecting flora consist of aerobic, facultative, and anaerobic gramnegative bacilli, various streptococci and enterococci, and an excess of gram-positive anaerobes [4] [5] [6] .
IAIs are typically managed using surgical intervention in conjunction with antibiotic therapy [7, 8] . Piperacillin/tazobactam and ertapenem showed equivalence in a randomized controlled trial (RCT) and are commonly used in the treatment of IAIs [9] . Piperacillin is an extended spectrum beta-lactam antibiotic, together with the beta-lactamase inhibitor tazobactam. It has activity against many gram-positive, gram-negative pathogens, and anaerobes. Ertapenem is a novel Group 1 carbapenem that offers once-a-day monotherapy and its activity includes the majority of bacterial pathogens causing most routine communityacquired infections, including enterobacteriaceae and anaerobes.
The problem with antibiotic therapy is the causal relation between antibiotic use and the development of antimicrobial resistance (AMR) [10] [11] [12] [13] . With each beneficial application of these treatments there is the increased likelihood that any antibiotic will be less effective for repeated use in the future both for patients who have been treated with the particular antibiotic before and for new patients as well. AMR may lead to treatment failure in the management of IAI when the antibiotic agent to which the causative agents are resistant to, is used [14] . Enterobacteriaceae (e.g., Escherichia coli) are major pathogens in IAI [1, 9] . Over the last decade, resistance to beta-lactams among these organisms mostly because of extended spectrum betalactamases (ESBL) production has become common both in the hospitals, and more recently also in the community. These organisms often fail treatment with various beta-lactam agents, whereas carbapenems, such as ertapenem, retain activity against ESBL-producing organisms [15, 16] . In the Dutch population the overall prevalence of confirmed ESBL producers close to 6% can be considered significant [17] . More than 40% of all isolates were identified as E. coli. The study for monitoring antimicrobial resistance trends (SMART)-an ongoing global antimicrobial surveillance program focused on clinical isolates from IAIindicates that in Europe about 4% of E. coli is ESBL producing in community-acquired IAI and 8% in hospital acquired infections. In Europe the sensitivity of E. coli to piperacillin/ tazobactam is about 95% whereas ertapenem shows sensitivity close to 100% [18] . DiNubile et al. showed that ertapenem is ideal for the treatment of moderate to severe polymicrobial infections where ESBL producers are likely and shows minimal risk for development of AMR [19] . It is equally important to emphasize the relevance of anaerobes. In the trial comparing ertapenem with piperacillin/tazobactam, more than 30% of the pathogens were Bacteroides Fragilis and more than 70% other Bacteroides spp [9] .
Complicated IAI are associated with increased hospital resource consumption and costs [20] . In addition, the evolvement of selective bacteria has a negative impact on the financial burden. Significant cost-drivers related to AMR include cost related to treatment failure which leads to increased length of hospital stay, need for excess surgical procedures, other medical resource consumption, and optionally productivity loss, among others [21] . A mathematical model provides a valuable framework to link the (epidemiological/biological) dynamics of resistance with economic end points. With such a model the (future) resistance as well as the economic consequences can be estimated given certain treatment strategies [21] . Models for AMR have primarily been developed for nosocomial infections. The key assumption is that bacteria are transmitted between patients in hospitals via direct contact between patients, via human vectors, or through contamination of the environment [22] . Although the epidemiology of antibiotic treatment and resistance in the hospital setting is different than in the community, several studies have also found a positive association between antibiotic use and antibiotic resistance in the community [22, 23] . Furthermore, a study by Bruinsma et al. among healthy individuals in populations showed that living in an environment with resistant bacteria is a real risk for acquiring such bacteria, and more important, the closer the contact the larger the risk [23] . These results indicate that next to antibiotic prescription, population density is a factor influencing the prevalence of AMR. Hence, it can be argued that mathematical transmission models, as used for nosocomial infections are also applicable to model communityacquired infections [24] .
Given the economic burden of IAI and AMR, therapeutic decisions should be based on an evaluation of costs and benefits of available alternatives [25] . Hence, a cost-effectiveness evaluation, by which the value for money of antimicrobials can be assessed, is warranted. This study describes the cost-effectiveness analysis of ertapenem relative to piperacillin/tazobactam for the treatment of community-acquired complicated IAI for The Netherlands from a limited societal perspective (i.e., only direct costs). Furthermore, we illustrate how AMR can be taken into account and how this changes over time, thereby influencing cost-effectiveness.
Methods

Model Structure
Two integrated models were developed: 1) A Susceptible-Infected-Susceptible (SIS) model for the development of AMR (i.e., reduced sensitivity/effectiveness over time) with ertapenem and piperacillin/tazobactam in community-acquired IAI [21] ; and 2) a decision tree to evaluate the cost-effectiveness of ertapenem relative to piperacillin/tazobactam for the treatment of these infections given the level of AMR obtained from the SIS model.
Development of antibiotic resistance: SIS-model. The SIS model
is a type of mathematical model consisting of compartments and reflects the dynamic changes in the uninfected population and those infected with sensitive and resistant strains. Figure 1 presents the used SIS compartment model for AMR over time for one antibiotic. The model makes specific assumptions about the transmission of antibiotic-sensitive and resistant bacteria among hosts and the course of the infection. More specific, AMR develops as a function of pathogen virulence, infected fraction with a susceptible strain and a resistant strain, rates of recovery, and prescription.
Three compartments can be differentiated whose sizes change over time: uninfected or susceptible hosts (S); hosts infected with a sensitive strain (Iw) and hosts infected with a resistant strain of bacteria (Ir). We assume there is a constant population size; in other words all the people in the population are the same people from period to period (Eq. 1)
Uninfected hosts can become infected with a sensitive or resistant strain. As indicated by Bruinsma et al. transmission of strains is a function of population density [23] . The rate of transmission to uninfected hosts is determined by the density of uninfected and infected hosts as well as a transmission rate parameter (b) according to bS(Iw + Ir). The greater the population density is, the greater the transmission rate parameter. [Please note that this construct involves multiplying two complementary fractions, whose product is always greatest when both S and Iw + Ir involve middle values, for example 0.5 ¥ 0.5 = 0.25, rather than when extreme values are assumed (0.9 ¥ 0.1 = 0.09)]. The spontaneous rate of clearance of bacteria from infected hosts can be different for sensitive and resistant strains, reflected with rw and rr. We assumed that antibiotic treatment accelerates the clearance of sensitive strains with rate h. The reciprocals of the clearance rates represent the duration of infection, and therefore the period of time in which hosts transmit the bacteria. The change in the density of uninfected and infected hosts is reflected with the arrows in Figure 1 . Given the greater clearance rate of sensitive strains under antibiotic treatment than for resistant strains, the fraction of hosts with resistant strains will increase over time relative to the fraction of hosts with sensitive strains, thereby resulting in an increased AMR over time.
The changes in the transmission rates as a function of the fraction (i.e., size of compartment) of hosts uninfected and infected over time as illustrated in Figure 1 can be described by the following differential equations: 
For the current model we have assumed that the spontaneous rate of clearance for sensitive strains is the same as for resistant strains.
Δr r r r w = − = 0 (5) The sensitivity of strains to the antibiotic can be expressed with w according to:
By combining the equations 3, 4, 5, and 6 the changes in sensitivity (i.e., 1-resistance) over time can be extracted according to Eq. 7 as shown by Laxminarayan and Brown [21] dw dt f h r w w = − ( ) − ( ) 1 (7) The output of the SIS model we are interested in is the sensitivity of bacteria to the antibiotic by month as a function of the antibiotic prescription distribution (f, this can be called the treatment strategy), initial resistance (1 -wt=0), spontaneous rate of clearance (r), and rate of clearance under antibiotic treatment (h). The larger the proportion of patients that get a certain antibiotic prescribed, the more rapid resistance will develop. Note again that this construct involves multiplying two complementary fractions (w and w-1) and suggests that the rate of increase in resistance is likely to be most pronounced when the initial resistance is neither too low nor too high. The factors r and h remain constant over time and are the same for both antibiotics (please note from Eq. 7 that the fraction of hosts infected as well as the transmission rate is not of relevance). The sensitivity over time translates into a corresponding efficacy according to: 
where p success0 is fraction of infected patients that are successfully treated according to clinical criteria with antibiotic 1 at t = 0 (initial effectiveness) p successt is fraction of infected patients that are successfully treated according to clinical criteria with antibiotic 1 at month t Decision tree to evaluate cost-effectiveness. The decision tree in Figure 2 describes the treatment pathway and outcomes relevant to treatment of IAI. Both ertapenem and piperacillin/tazobactam can result in a successful outcome with a certain probability. A clinical success was defined as resolution of the infection, with no further antibiotic therapy necessary [9] . The clinical success is related to the sensitivity of the strains to the antibiotic that can vary by month as a result of development of AMR. In case of a clinical failure, a second antibiotic will be prescribed which again has a certain probability of success. If this second antibiotic treatment fails, the outcome can be either fatal or there will be sequelae as a result of the bacterial infection. It is assumed that all events after the prescription of the antibiotic of choice occur within 1 month. Output variables of the decision tree are: drug acquisition costs (discounted); cost of other resource consumption [i.e., length of stay, surgery, and outpatient visits] (discounted); total cost (discounted); mortality and (quality adjusted) life years lost (discounted); incremental costs; effectiveness; QALYs saved; and incremental cost-utility ratios. These output estimates will vary over time as a function of developing resistance for both ertapenem and piperacillin/tazobactam.
Input Data
Dynamics of antimicrobial resistance. Input data used for the SIS model includes information on the rate of eradication in presence of antibiotic treatment (h), the spontaneous clearance rate (r), and the initial resistance of bacteria (1 -wt=0) to ertapenem and piperacillin/tazobactam (see Table 1 ). •Infected hosts can be infected with either a sensitive strain (I w ) or with a resistant strain of bacteria (I r ).
) (
•Clearance of a sensitive or resistant strain without antibiotic treatment is determined by a spontaneous clearance rate (r w and r r )
•Clearance with a specific antibiotic is determined by the rate of clearance under antibiotic treatment (h) and fraction (f) treated.
•h is greater than r w and r r •Susceptibility of strains to antibiotic is defined as w = I w /(I w + I r )
•Given the greater clearance rate sensitive strains under antibiotic treatment than for resistant strains, the fraction of hosts with resistant strains will increase over time relative to the fraction of hosts with sensitive strains. Hence sensitivity (w) of strains will decrease over time (i.e. AMR will increase).
•w is used to calculate reduction in clinical efficacy over time (as used in decision tree)
according to: The daily clearance rate with first line antibiotic treatment (h) was calculated as 0.137, based on the average duration of colonization of 7.3 days with ertapenem and piperacillin/ tazobactam [9] . This corresponds to a probability of 0.984 that the bacteria are eradicated at the end of the month. The spon-taneous daily clearance rate (r) was 0.103 under the assumption that the duration of colonization under treatment was 75% of the duration without treatment, i.e., about 10 days. (Furthermore, after 10 days without success, a second line antibiotic was assumed to be given.) This corresponded to a Cost-Effectiveness of Ertapenem probability of 0.956 that the bacteria are eradicated at the end of the month. Initial resistance (which equals 1 minus the fraction of sensitive strains) was based on the distribution of pathogens among patients with IAI as in the RCT by Solomkin et al. [9] ; the most frequent isolates were E. coli (about 70%), Bacteroides fragilis (35%), other Bacteroides spp (73% in ertapenem group and 82% in piperacillin/tazobactam group), and Clostridium spp (33%). Initial resistance (1 -wt=0) with ertapenem was calculated as 0.064: Solomkin et al. showed 92.1% biological and clinical response [9] . This percentage is the combination of clearance under antibiotic treatment and the fraction of hosts with sensitive strains. Hence, susceptibility is calculated by dividing 0.921 with the 0.984 probability that the bacteria are eradicated at the end of the month (see above). Initial resistance with piperacillin/ tazobactam was calculated as 0.106: Solomkin et al. showed 88% biological and clinical response [9] . Hence, susceptibility is calculated by dividing 0.88 with the 0.984 probability. The analyses included pathogens intrinsically resistant to ertapenam such as enterococci and pseudomonas aeruginosa, and those with intrinsic or acquired resistance to piperacillin/tazobactam.
Since E. coli is in community-acquired IAI, the most common EBSL-producing pathogen, an alternative analysis was performed using AMR data for E. coli in community IAI as obtained from SMART [18] . Worldwide the sensitivity of E. coli to piperacillin/tazobactam was 0.969 for community-acquired infections and 0.944 for community and hospital infections combined (2004 data on file), hence a difference of 0.025. In Europe the sensitivity of E. coli to piperacillin/tazobactam was reported to be 0.953 for community and hospital infections combined. When assuming this 0.025 difference also applicable to Europe we obtain an estimate of 0.978 for piperacillin/tazobactam for community-acquired IAI, or an initial resistance of 0.022. For ertapenem there is similar sensitivity for community and hospital acquired infections. Hence, we assumed the reported sensitivity of E. coli to ertapenem of 0.997 also valid for communityacquired IAI; i.e., an initial resistance of 0.003.
Efficacy, life expectancy, and resource use and cost data. Table 1 also lists the input data for the decision tree. Efficacy of ertapenem and piperacillin/tazobactam were extracted from the RCT by Solomkin et al. [9] . In the model these efficacy estimates were used for the initial analysis of the cost-effectiveness. Over time the efficacy estimates will decrease as a function of AMR. When ertapenem or piperacillin/tazobactam was not efficacious according to the trial definitions of clinical response, patients were treated with another (second line) antibiotic treatment: imipenem/ cilastatin. The efficacy of imipenem/cilastatin was obtained from Dietrich et al. and assumed constant over time [26] . This study also provided information to assume a mortality of 5%. Mortality was based on second-line failure and therefore, the mortality was divided by the probability of failure of second-line treatment.
Given the average age of 45 years of the patients studied by Solomkin et al. [9] , a life-expectancy of 35 years can be expected when a patient does not die because of the IAI (Centraal Bureau Voor de Statistiek [CBS] statline). Given the average age of the population we did not assume a disutility value for the life years expected when a patient survived an episode of IAI. As a result the discounted life years are the same as the discounted quality adjusted life years, i.e., 27.5 QALYs.
Based on Solomkin et al. [9] the average treatment duration with ertapenem (1 g per day) was 7.6 days and with piperacillin/ tazobactam (9 g per day) 7.8 days. (In the trial therapy was given for a minimum of 4 full days, unless treatment failure was identified earlier, and the suggested maximum duration was 14 full days.) This is in line with guidelines for IAI. [1] Based on Krobot et al. failure patients were assumed to be treated for 8 days with imipenem/cilastatin (3 g) [27] . With successful treatment with ertapenem or piperacillin/tazobactam, the average length of hospital stay was 12 days, and without success, i.e., need for second line treatment, 22 days [28] . Costs for the surgical intervention were based on the DRG system for The Netherlands (DBC) and it was assumed that all patients had two outpatient visits. All costs were (inflated to) 2006 costs.
Analysis
Three series of analyses were performed: 1) a base case scenario with resistance data extracted from Solomkin et al. [9] ; 2) an alternative scenario based on E. coli resistance data from SMART and similar initial efficacy; and 3) and a scenario with a similar initial resistance for piperacillin/tazobactam as for ertapenem, but different initial efficacy.
Expected costs and QALYs with ertapenem were compared with those expected for piperacillin/tazobactam at different points in time. We made the assumption that all IAI patients over a period of 60 months used either only ertapenem or only piperacillin/tazobactam. Results were presented for 5 points in time, (month 1, 15, 30, 45, and 60). Initial analysis (i.e., month 1) was performed using efficacy data as reported by Solomkin et al. [9] . For the following months, reduced efficacy data were obtained from the SIS model. In the analysis a discount rate of 4% was used for costs and 1.5% for QALYs.
The source data are characterized by uncertainty. To incorporate uncertainty in the evaluation, a probabilistic sensitivity analysis (PSA) was performed to quantify the uncertainty in model outcomes for each scenario of the SIS model. A random value was repeatedly sampled from distributions reflecting the uncertainty level of the input source data, plugged into the model, and then the outcome of the model was calculated. For initial efficacy of first line treatment and mortality, beta distributions were used. For dose and treatment duration, length of hospital stay, and other medical resource use costs triangular distributions were used given the lack of data in the literature. Each outcome was presented with a point estimate along with uncertainty reflected by the 2.5th and 97.5th percentile of the uncertainty distribution. Acceptability curves were created to estimate the probability that ertapenem would be cost-effective in comparison to piperacillin/tazobactam for different willingnessto-pay ratios, defined as the assumed maximum amount a decision maker would be willing to pay for a unit of benefit (QALY).
Results
Antibiotic Resistance, Sensitivity and Efficacy over Time
Under the base-case scenario, the initial resistance of ertapenem and piperacillin/tazobactam was 0.064 and 0.106 and it is expected that, over time, the resistance will increase with a slightly greater rate with piperacillin/tazobactam. In Figure 3 , the corresponding sensitivity of bacterial strains to ertapenem and piperacillin/tazobactam is presented as well as the related expected efficacy. Initial efficacy of 0.867 with ertapenem and 0.812 with piperacillin/tazobactam is expected to change to 0.680 and 0.558after 5 years when all patients are prescribed with the same antibiotic.
Under the alternative scenario based on European SMART data, the initial resistance of ertapenem and piperacillin/ tazobactam was 0.003 and 0.022 and is expected to increase only slightly over time (See Figure 4) . Given the smaller difference in resistance, it is also expected that the difference in efficacy between the two treatments will be smaller: 0.867 for ertapenem at baseline and 0.856 at 5 years of follow-up, and for piperacillin/tazobactam 0.867 at baseline and 0.793 at 5 years of follow-up. In Figure 5 , results of the scenario are presented where ertapenem and piperacillin/tazobactam have the same initial resistance, 0.064, which increases to 0.266 at 5 years of follow-up, but different initial efficacy. The efficacy reduces over time from 0.867 at baseline to 0.680 at 5 years for ertapenem, and reduces from 0.850 at baseline to 0.667 at 5 years for piperacillin/tazobactam.
Quality Adjusted Life Years, Costs and Cost-Effectiveness
In Table 2 , the expected QALYs, drug costs and total treatment costs are presented by treatment arm under the base-case scenario. Over time the expected QALYs will decrease and costs will increase for both treatments, although at a greater rate for piperacillin/tazobactam. In Table 3 , the difference in costs and QALYs are presented. The model suggested overall savings of €355 (95% uncertainty interval €-480; €1205) per patient when IAI are treated with ertapenem instead of piperacillin/ tazobactam. After 5 years, the cost-savings with ertapenem are expected to increase to €672 (€-232; €1617), and ertapenem will additionally result in greater QALYs (0.17; 0.07-0.30). The probability of the incremental cost per QALY gained being within a threshold for cost-effectiveness (€20,000) was initially 94% and increased to >99% at 5 years ( Figure 6 ).
In Table 4 , the difference in costs and QALYs are presented when the development of resistance is estimated according to the SMART data, and similar initial efficacy. Overall savings of €94 (€-760; €893) per patient when IAI are treated with ertapenem instead of piperacillin/tazobactam are expected. After 5 years, the cost-savings with ertapenem are expected to increase to €395 (€-454; €1186), and ertapenem will result in 0.09 (0.01; 0.21) additionally QALYs. Under a scenario with similar initial resistance, the costs difference favoring ertapenem will slightly decrease because of discounting, and the difference in QALYs, slightly favoring ertapenem as well, will remain constant over 5 years (See Table 5 ).
Discussion
The current evaluation showed that ertapenem, relative to piperacillin/tazobactam, is a cost saving and possibly an economically dominant treatment for community-acquired complicated IAI in The Netherlands. The prescription of antibiotic treatment is associated with AMR. With the current study, we illustrated how development of AMR can be incorporated in a cost-effectiveness evaluation of antimicrobial therapy. If the AMR of ertapenem and piperacillin/tazobactam as extracted from the ertapenem trial [9] is considered applicable to The Netherlands, it is expected that the AMR of piperacillin/tazobactam will develop at a greater rate than the AMR with ertapenem. As a result, cost savings and QALY gains with ertapenem will increase over time. If the AMR for ertapenem and piperacillin/tazobactam in The Netherlands is more in line with the European data of the SMART study (i.e., smaller absolute AMR and a smaller difference) the development of AMR over time for both treatments will be at a much smaller rate and the difference in costs and QALYs between ertapenem and piperacillin/tazobactam will be smaller, still favoring ertapenem though. If there is no difference in the AMR of ertapenem and piperacillin/tazobactam, the development of AMR over time is the same for both interventions. As a result, the absolute responses are decreasing, but the difference in efficacy as shown by Solomkin et al. remains constant over time [9] . Transmission SIS models have been used to evaluate the impact of prophylaxis and treatment of nosocomial bacterial infections on the development of AMR. Given the objective of the study to evaluate the cost-effectiveness of treatment of community-acquired IAI, and the notion that AMR is increasing in the community, we opted to also use a compartment model to capture the development of AMR in this community-acquired infection and to evaluate its impact on the cost-effectiveness. One can argue that an important epidemiological difference between hospital-acquired infections and community-acquired infections is that a hospital has highly dynamic populations, unlike communities in which resistance is studied [22] . Nevertheless, it has been shown that population density does have a relation with the prevalence of AMR [23] . Similar to the hospital environment, living in close contact with other persons harboring resistant pathogens is a risk factor for AMR in the community [23] .
Hence, the use of a transmission model for AMR in the community can in our opinion be defended. Of course, these transmission models do not aim to provide a precise reflection of these processes in real communities, but rather, in a quantitative manner can help evaluate the consequences of antibiotic prescription over time, e.g., development of resistance in a nonlinear fashion, and the greater the AMR the greater the rate of future development with antibiotic use.
To develop a model for the treatment of IAI taking into account development of AMR, several simplifications and assumptions were made with respect to actual routine practice. First, with the SIS model, the increase in AMR was primarily a function of the (initial) fraction of the population infected with resistant strains out of the total infected population, and the difference in recovery rate between resistant strains and sensitive strains. Nevertheless, in bowel colonization studies, the frequency of colonization with resistant enterobacteriaceae substantially increased in patients treated with piperacillin/tazobactam but not in patients treated with ertapenem. Hence, the SIS model does not capture the difference in resistance profile between ertapenem and piperacillin/tazobactam, which probably has resulted in an underestimation of the cost and QALY advantages observed with ertapenem over time. Second, prescription of imipenem/cilastatin as a second line antibiotic treatment after an ertapenem or piperacillin/ tazobactam failure did not influence AMR for imipenem/ cilastatin, and therefore the efficacy of imipenem/cilastatin remained constant over time. A third simplification compared to routine practice is the assumption that all patients with IAI are treated with piperacillin/tazobactam or all patients are treated with ertapenem. Since, the frequency of prescription influences the development of AMR, these 100% "prescription-of-oneantibiotic-for-all-IAI" scenarios most likely have resulted in an overestimation of the development of AMR for both ertapenem and piperacillin/tazobactam. As outlined above, the prescription of another antibiotic for the population of patients with IAI-e.g., ceftriaxone/metronidazole-decreases the rate of development for ertapenem and piperacillin/tazobactam. On the other hand, resistance to ceftriaxone is co-linked to resistance to piperacillin/ tazobactam but not to resistance to ertapenem [19] , thereby increasing AMR at a greater rate with piperacillin/tazobactam then what is expected based on the prescription of piperacillin/ tazobactam.
We opted for a decision tree to reflect the economic consequences of IAI treatment. Alternatively, a Markov structure with different health states seems an interesting alternative. Such a structure probably enables a more realistic approach to the course of treatment and outcomes. For example, Edwards et al. used such an approach for a cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care [29] . The disadvantage of a Markov model, however, is the methodological challenge in linking such a model with the SIS compartment model, thereby possibly limiting the transparency of the overall modeling work.
In addition to using a decision tree, some other model structure related simplifications were made. First, the assumption of a utility value of 1 for the expected life years when a patient survived an IAI can be argued to be optimistic, and the average utility for the remaining life expectancy might possibly be somewhat lower, e.g., 0.9. Nevertheless, a utility value of 0.9, by which the QALY estimates will be reduced by 10%, would still have resulted in economically dominant findings. Second, no difference in the life expectancy was assumed for a patient that was successfully treated and a patient that has sequelae. Since, the probability of sequelae was lower for ertapenem relative to piperacillin/tazobactam (respectively 1.6% and 2.3% at month 1, and 3.9% and 5.4% at month 60) this simplification has resulted in an underestimation of the life years gained with ertapenem relative to piperacillin/tazobactam, if there is a difference in life expectancy between patients with and without sequelae. On the other hand, we did not differentiate the average utility between these types of patients, which could have resulted in some overestimation of the average utility for both treatments, thereby overestimating the average utility gained with ertapenem. Nevertheless, in combination, the assumption of a similar life expectancy and utility for patients with and without sequelae did most likely not bias the estimate of the QALYs gained with ertapenem relative to piperacillin/tazobactam. A third simplification was that adverse events were not taken into consideration, and the impact on treatment switches. This decision was driven by the similar proportion of adverse events seen with ertapenem and piperacillin/tazobactam and the adverse events that occurred were mild and not associated with extensive costs [9] .
Apart from choices regarding the model structure, input data are another source of uncertainty, either because of sampling error or simply because of lack of data thereby making assumptions or relying on expert opinion. With the large number of input data, quantifying the uncertainty associated with the costeffectiveness estimates is essential for the validity of the models. Although single and multiway sensitivity analysis may be used to investigate the effect of different model parameters, only PSA allows for the interaction of different sources of uncertainty present within a model. In the current evaluation we only defined uncertainty distributions for the parameters of the decision tree. With multiple scenarios the impact of changes in the rate of development of AMR was evaluated. Although this helps understanding the impact of the development of AMR over time, the overall uncertainty in the cost-effectiveness estimates beyond the first month of treatment is underestimated. For future analysis, it suggested to define uncertainty distributions for both parameters of the SIS compartment model as well as the decision tree, and to evaluate these simultaneously.
A drawback of the current evaluation is that only one trial was used as a source for efficacy estimates for ertapenem and piperacillin/tazobactam [9] . Recently two similar, but smaller, trials were published [30, 31] . Hence, combining the results of the three available studies by means of meta-analysis, and using the obtained pooled estimates for the cost-effectiveness analysis is of interest and will improve the analysis. Nevertheless, we do not expect that these pooled results will result in different conclusions. First, despite the absence of significant differences favoring ertapenem in these trials, a pooled estimate will still reflect a relative efficacy estimate (numerically) favoring ertapenem because of the larger sample size of the Solomkin trial [9] . Second, in our alternative scenario analysis, we used smaller differences in efficacy than those reported by Solomkin et al., and this still resulted in economic outcomes favoring ertapenem.
Model parameter f is an important factor for the development of AMR, and therefore for changes in cost-effectiveness over time. In the presented analyses the costs and benefits of the two treatments were compared at different points in time by assuming situations where all patients were treated with either piperacillin/ tazobactam or ertapenem. In other words two strategies were compared with either 100% ertapenem, or 100% piperacillin/ tazobactam over time. Based on this assumption, it is likely that if all patients were treated with ertapenem, the resistance to piperacillin/tazobactam will not increase any further, in contrast to ertapenem. At a certain point the sensitivity of bacteria to ertapenem will become lower than for piperacillin/tazobactam, as illustrated in Figure 5 . From an AMR point of view it seems preferable to prescribe both antibiotics (50% ertapenem and 50% piperacillin/tazobactam) to the patient population of interest from that point onwards. As a result of this "50/50 prescription," AMR continues to develop less rapidly than when only one antibiotic is prescribed in the population (See Figure 7) . As a result, the effectiveness over time of the combined strategy will remain greater than of piperacillin/tazobactam or ertapenem alone. When such a strategy is compared with a strategy of only piperacillin/tazobactam the cost-savings are €482 at 30 months combined with 0.13 QALY savings. At 60 months, the costsavings are €1003 and 0.28 QALYs savings. At 30 months the 50/50 prescription strategy is €20 more expensive than the ertapenem only strategy and results in similar QALYs. At 60 months, €330 will be saved combined with 0.11 QALYs saved. Overall, these findings imply that both from a cost-effectiveness point of view as well as a resistance point of view it seems reasonable to recommend using ertapenem as an alternative to piperacillin/ tazobactam, until comparable resistance shows. From that point onwards a 50/50 strategy is preferred. To develop this notion further, interesting questions from a policy perspective that in principle can be answered with the approach illustrated in this article are for example: "What is the optimal initial market share of use of ertapenem that would yield the lowest growth in resistance (as per equation 7)?" or "What about combining ertapenem with other antibiotics, such as those that may offer complementary coverage for microbes not covered by ertapenem, such as pseudomonas, which incidentally, is also of some importance in IAI?" Although the modeling work here may be sufficient to discern some overall trends, caution has to be made to make specific policy recommendations. Many treatment options are relevant for community-acquired IAI [1] . Recommended regimens for patients with more severe infections include meropenem, imipenem/cilastatin, third-or fourth-generation cephalosporins plus metronidazole, ciprofloxacin plus metronidazole, and piperacillin/tazobactam. For the current study we focused on this latter treatment given the availability of head-to-head data for efficacy. For future analysis, it is of interest to elaborate on the analyses by including a range of different interventions based on indirect comparisons, and to evaluate what is the most costeffective prescription strategy over time considering differences in AMR.
In conclusion, given the underlying assumptions and data used, this economic evaluation demonstrates that ertapenem is a cost-saving and possibly an economically dominant therapy over piperacillin/tazobactam for the treatment of communityacquired complicated IAI in The Netherlands. Although the prevalence of ESBL producing organism is expected to be relatively low in community-acquired infections in The Netherlands, any difference in AMR between ertapenem and piperacillin/ tazobactam will result in increasing cost and outcome differences over time favoring ertapenem. Accounting for development of AMR as a function of prescription in cost-effectiveness evaluations can help answer interesting questions from a policymaking point of view. Research to overcome some methodological challenges is desirable. Development of resistance to ertapenem and piperacillin/tazobactam with different prescription strategies: 1) piperacillin/tazobactam only; 2) ertapenem only; or 3) only ertapenem is prescribed until the point when resistance is the same as with piperacillin/tazobactam, followed by a "50/50 prescription."
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